Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib Study of the Safety, Pharmacokinetic of Lisaftoclax (APG-2575) Single Agent and in Combination With Homoharringtonine or Azacitidine in Patients With Relapsed/Refractory AML

NCT04501120 is registered in ClinicalTrials.gov with Ascentage Pharma Group Inc. as lead sponsor.

NCT NCT04501120
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04501120 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib Study of the Safety, Pharmacokinetic of Lisaftoclax (APG-2575) Single Agent and in Combination With Homoharringtonine or Azacitidine in Patients With Relapsed/Refractory AML
Lead sponsor
Ascentage Pharma Group Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 28, 2020
Completion date
September 30, 2029
Enrollment
682 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

myeloid malignancy, relapsed/refractory acute myeloid leukaemia